Medication Reconciliation in Oncologic Patients

Medication Reconciliation Clinical Trial

— PROF2  

Official title:

An Integrated Model to Increase Medication Recognition and Reconciliation in Oncologic Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04796142
• Other study ID #: IRST 100.40
• Status: Recruiting
• Phase: N/A
• Start date: June 12, 2019
• Est. completion date: June 15, 2022

Study information

• Verified date: March 2021
• Source: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
• Contact: alessandro passardi
• Phone: 0543739100
• Email: alessandro.passardi[@]irst.emr.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To improve medication reconciliation in oncologic patients in healthcare transitions through an alliance between a Cancer Institute and the community pharmacies and a new integrated IT platform.

Description:

This trial will explore the alliance between a Cancer Institute and the community pharmacies to improve medication reconciliation in healthcare transitions, and will validate a new integrated IT platform.

Cancer patients receiving an oncologic treatment will be asked to choose a pharmacy participating to the trial, and to perform the pharmacological survey before every cycle of chemotherapy.

This will be sent through the new IT platform to the electronic medical record of IRST, and the Oncologist will perform the reconciliation.

Data about concomitant medications and possible interactions will be exensively analyzed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 15, 2022
• Est. primary completion date: January 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult =18 years old

• Eastern Cooperative Oncology Group (ECOG) performance status =1

• Patients receiving an anticancer treatment

• Clear understanding of the Italian language; written informed consent.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Medication Reconciliation

Intervention

Other:
• medication reconciliation
medication reconciliation

Locations

Country	Name	City	State
Italy	Alessandro Passardi	Meldola	FC

Sponsors (1)

Lead Sponsor	Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	medication recognition and reconciliation maintenance	number of reconciliations per patient	At day 1 of each cycle of treatment (each cycle might be 14, 21 or 28 days)